However, commercial coverage still ranges from strong coverage to total exclusion
So the realistic picture of running both concurrently is a few weeks of additive appetite suppression that fades, layered onto a chronic therapy, with cumulative cardiovascular and stimulant risk that does not fade on the same schedule
June 2026: The GLP-1 NAION federal group claim (called an MDL) has 110 lawsuits in it
GIP receptor activation enhances insulin secretion, modulates adipose tissue metabolism, and appears to synergise with GLP-1 activity to produce greater metabolic effects than either hormone alone as demonstrated by the clinical performance of the dual agonist tirzepatide
GLP-1-Ts ability to lower liver fat adds to its comprehensive profile as a metabolic health intervention
The pharmacy I use is US-based, cGMP-certified, and issues a certificate of analysis with every batch